Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

GE Healthcare, Beckman Coulter, Boston Scientific, Purdue University, University of Illinois present engineering innovations at MEDCon

January 4, 2011 5:46 am | News | Comments

Medical Electronic Device Conference & Expo (MEDCon) will be held May 16-18, 2011 at Navy Pier in Chicago, IL.  This event provides the opportunity to stay at the forefront of innovations in engineering for electronic medical devices.

TOPICS:

Atrium acquires dietary supplement marketer Seroyal, shares rise seven per cent

January 4, 2011 5:45 am | by The Associated Press | News | Comments

Shares in Atrium Innovations Inc. (TSX:ATB) rose more than seven per cent in early trading after the company said it had acquired dietary supplement marketer Seroyal International for US$110 million in cash.Atrium shares jumped $1.12 to $16.34 in morning trading on the Toronto Stock...

Celgene seeks approval for blood cancer treatments

January 4, 2011 4:45 am | by The Associated Press | News | Comments

Celgene Corp. said Tuesday it submitted for approval blood cancer treatments Revlimid and Istodax to European and U.S. regulators, respectively.The Summit, N.J., company is seeking approval for Revlimid from the European Medicines Agency to treat multiple myeloma patients who have not progressed...

Advertisement

Satori socks away $7M in new $20M funding

January 4, 2011 4:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Satori Pharmaceuticals Inc., a Cambridge-based developer of drugs for neurodegenerative disorders, has raised $7 million in a new round of financing that is targeting $20 million, according to federal documents.

NxStage to Present at the 29th Annual J.P. Morgan Healthcare Conference

January 4, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., Jan. 4, 2011 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer and Robert S. Brown, Chief Financial Officer, will present at the 29th Annual J.P. Morgan...

TOPICS:

PneumRx, Inc. Raises $33 Million in Capital

January 4, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /- PneumRx, Inc. ( www.pneumrx.com ), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has raised $33 million in working capital commitments.  The oversubscribed...

TOPICS:

PositiveID Corporation and Siemens AG Enter Into Agreement to Expand PositiveID's Wireless Body Platform

January 4, 2011 4:34 am | by PositiveID | News | Comments

Siemens' Intellectual Property to Broaden Applications to Improve Disease Management

TOPICS:

Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants

January 4, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., Jan. 4, 2011 /- Arstasis is pleased to announce the Arstasis One Access Device is available to physicians, nurses, patients, and cath lab technicians across the United States.  Until now, only a select number of physicians participating in Arstasis clinical...

TOPICS:
Advertisement

Graymark Healthcare's Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010

January 4, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

OKLAHOMA CITY, Jan. 4, 2011 /- Graymark Healthcare Inc. (Nasdaq: GRMH ), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), serviced a record number of OSA patients in the fourth quarter of 2010, with...

TOPICS:

Federal Register: Informed Consent Elements

January 4, 2011 4:30 am | by U.S. Food & Drug Administration | News | Comments

The FDA is amending the current informed consent regulations to require that informed consent documents and processes for applicable drug (including biological products) and device clinical trials include a specific statement that clinical trial...

TOPICS:

Thornton returns to Ziopharm Oncology

January 4, 2011 3:45 am | by The Associated Press | News | Comments

Ziopharm Oncology Inc. said Tuesday that Mark O. Thornton has returned to the company to become executive vice president and chief development officer.Thornton will report to CEO and Chief Medical Officer Jonathan Lewis and will oversee the product development process. The executive is...

Marina Biotech, Inc. to Present at Biotech Showcase 2011

January 4, 2011 3:45 am | by The Associated Press | News | Comments

Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will present at Biotech Showcase 2011 on Tuesday, January 11, 2011, at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) at the Parc 55 Wyndham San Francisco Union...

Digirad Receives CE Mark for ergo(TM) Solid-State, General Imaging Nuclear Medicine Camera

January 4, 2011 1:45 am | by The Associated Press | News | Comments

Digirad Corporation (NASDAQ: DRAD) today announced that it has received Conformite Europeene (CE) Mark approval enabling the Company to market and distribute its ergo large field-of-view, general-purpose portable imaging system throughout Europe and other countries governed by the CE...

STAAR Surgical's Visian® ICL Surpasses 200,000 Implants

January 4, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

MONROVIA, Calif., Jan. 4, 2011 /- STAAR Surgical Company (Nasdaq: STAA ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000.  Since...

TOPICS:

MEMSIC, INC. (NASDAQ: MEMS) closes above 200-day moving average, hits $3.40

January 3, 2011 11:36 pm | by I-Micronews | News | Comments

Shares of MEMSIC, INC. (NASDAQ: MEMS) closed above its 200-day moving average on Friday. The stock has a 200-day moving average of $2.70 and last traded at $3.40.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading